Allergy & Immunology
QY201, a Dual JAK1/TYK2 Inhibitor, Shows Promising Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis: Phase 2 Dose-Finding Trial Results
In a phase 2 trial, oral QY201 significantly improved skin outcomes in moderate-to-severe atopic dermatitis with favorable safety, supporting further phase 3 evaluation.
